Replies to post #117206 on Biotech Values

[poorgradstudent]

OT:

For a select few, perhaps, but for the average of US-based large-cap firms, 10% is not even close.

In the drug/biotech industry, the income-tax rate for the parent company (which pays a mix of country-specific rates) is typically between 20% and 30%.

Yes, my fault. I was going off a weak memory.

The stat (circa 2008) is that ~35% of corporations pay less than 10%. Still a substantial amount, although my number was clearly off.

Nonetheless, I think the thrust of my post stands. Dropping the corporate income tax rate is not going to stop companies from trying to find ways around paying. I think there are ethical issues to this as well, but that just makes me some type of bleeding heart or something.